AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03204604 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Testing - FCSRT
Description: The Free and Cued Selective Reminding Test (FCSRT) measures verbal memory through multiple trials of a list learning task. A list of 16 items is visually presented to the participants, who then recall as many items as possible. On subsequent trials, participants are told only those items they omitted on the previous trial. The procedure continues until the participant recalls all items on two subsequent trials. After approximately 30-minute delay, participants are asked to recall as many items as possible. The number of items recalled after the delay is then summed.
Study NCT03204604 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Story Recall
Description: Story Recall: This test is a modification of the episodic memory measure from the Wechsler Memory Scale-Revised (WMS-R). In this modified version, free recall of one short story that consists of 44 bits of information will be elicited immediately after it is read aloud to the participant and again after a thirty-minute delay. The total bits of information from the story that are recalled immediately (maximum score = 44) and after the delay interval (maximum score = 44) are recorded. Six comparable versions of this task have been validated in prior studies with older adults.
Study NCT03204604 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BVRT
Description: Benton Visual Retention Test (BVRT): The BVRT is a multiple-choice visual recognition task. Participants view a visual pattern and are then asked to select the target from an array of four patterns, three of which are distractors. It assesses visuospatial working memory. This recognition format has the advantage assessing visual memory while eliminating the influence of visuomotor and manual dexterity difficulties.
Study NCT03204604 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CogState One Card Learning
Description: The One Card Learning Test involves a visual learning task sensitive to early-stage cognitive impairment. It is one of several computerized assessments developed by CogState that assess executive function and working memory.
Study NCT03744702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Patients will receive IV ascorbic acid.
Study NCT03480451 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Multi-Disciplinary Patient Centered Rehab and Education
Description: This project is being withdrawn. No revisions to Intervention is available.~Patients will undergo consultation and education by members of a pre-determined multi-disciplinary team that aims to bring a predetermined set of services to the patient in a coordinated and scheduled manner in order to facilitate a comprehensive and through approach to the patient's entire well being
Study NCT03187405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVD + IVF with Alteplase
Description: Intraventricular fibrinolysis: Injection through the EVD of 1mg in 1 mL of Alteplase every eight hours during 3 days (9 doses).
Study NCT01145963 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control pasta
Description: control pasta
Study NCT01145963 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental pasta B
Description: experimental pasta
Study NCT01145963 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental pasta C
Description: experimental pasta
Study NCT04153695 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: to listen flamenco music during 30 minuts per day during 2 weeks
Study NCT03503396 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BAC Driving Feedback/Warning
Description: Participants will receive a warning at a set BAC limit, indicating they are too impaired to drive.
Study NCT03503396 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No Feedback
Description: Participants will receive no information about BAC, but will still complete study assessments and provide breath samples during drinking sessions.
Study NCT03952767 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Physical Measures and Survey Assessments
Description: Data from at home and in clinic visits will assess physical function and survey data will be collected
Study NCT02867228 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: changes in ventilator settings
Description: Ventilator settings will be adjusted (vent mode, pressure support/control level, cycling, inspiratory time, mandatory rate).
Study NCT00375466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Tranexamic acid 10 mg/kg as a bolus dose followed by an infusion of 1 mg/kg/hour. Bolus given before start of surgery, infusion continued during surgery.
Study NCT00375466 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0.9% sodium chloride 10 mg/kg, as a bolus injection before surgery followed by 1 mg/kg/h as an infusion during surgery
Study NCT03192137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISV-305
Description: Dexamethasone in DuraSite® 2 twice daily for 16 days
Study NCT03192137 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle twice daily for 16 days
Study NCT00622921 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Couples-based behavioral psychotherapy
Description: 12 weeks of Couples-based behavioral psychotherapy
Study NCT02789085 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ULF TENS stimulation
Study NCT00418093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given intravenously over 30 minutes on day 1 and day 15 of a 28-day cycle. Participants can continue study treatment as long as there is no disease progression.
Study NCT00418093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given intravenously over 2 hours on day 1 and day 15 of a 28-day cycle. Participants can continue study treatment as long as there is no disease progression.
Study NCT00418093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given intravenously over 30-90 minutes on day 1 and day 15 of a 28-day cycle. Participants can continue study treatment as long as there is no disease progression.
Study NCT03342937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin+Capecitabine+Pembrolizumab
Description: For each cycle: Oxaliplatin 130 mg/m2 IV on Day1, Capecitabine 825 or 1000 mg/m2 PO, BID Days on Days1-14, Pembrolizumab 200 mg IV on Day 1.~This study has 2 parts:~1. Safety validation part: all Cycles are 21 days in length.~2. Dose Expansion part: Cycle 1 is 28 days in length. Cycle 2 and beyond are 21 days.
Study NCT01079364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glulisine
Description: Pharmaceutical form: boxes of 5 SoloStar® pens Route of administration: injection Dose regimen: once a day
Study NCT01079364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Description: Pharmaceutical form: boxes of 5 SoloStar® pens Route of administration: injection Dose regimen: once a day
Study NCT01079364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Premixed insulin (Insulin Aspart 30/70 )
Description: Pharmaceutical form:boxes of 5 FlexPens Route of administration: Injection Dose regimen: twice daily
Study NCT04590053 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allocetra-OTS
Description: Allocetra-OTS is a cell-based therapeutic composed of donor early apoptotic cells, comprising allogeneic mononuclear enriched cell suspension with at least 40% early apoptotic cells. The suspension is prepared with Ringer's lactate solution and administered IV. It is stored at 2-8°C until 20+25 minutes before infusion and at room temperature thereafter. Each dose contains 140x10E6 ± 20% cells/ kg of recipient body weight (at screening) in a total volume of 375 mL in a transfer pack that undergoes irradiation and is administered via an adjusted filter using a volumetric pump, at a starting rate of 48 mL/hour with a gradual increase every 15-25 minutes of 15 mL/hour to a maximal rate of 102 mL/hour. The study intervention should be completed within 72 hours of completing the manufacturing process. During product administration, no other IV fluids such as Ringer's lactate or normal saline will be given in parallel unless medically indicated due to volume depletion.
Study NCT01984736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: EVP-6124
Study NCT01225120 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait Training
Description: 12 sessions, 30 minutes of walking on treadmill with real time therapist directed feedback on gait kinematics.
Study NCT03035994 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real-Time Biofeedback
Description: A custom written MatLab script will sample bilateral peak vertical ground reaction forces and display the magnitude in real time on a screen placed in front of the participant. A target line will be placed in the middle of the screen which corresponds to one of the three loading conditions. Participants will be instructed to alter their movement in an attempt to match each limb's vertical ground reaction force to the target line.
Study NCT02636387 — intervention group
Intervention type: DRUG
Intervention: Desmopressin
Description: Two desmopressin 0.2 mg tablets at bedtime for 14 days and monitoring if \<50 % improvement
Study NCT02623205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Participants randomized to the escitalopram group will be given the medication for 8 weeks, after which they will be given the option to continue for 4 more weeks if they are close to remission. This additional 4-week treatment option is something offered to participants outside the clinical trial, and therefore was not treated as part of the main study.
Study NCT02351960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole
Description: Dexlansoprazole capsules
Study NCT02623205 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: To reduce the burden of the patients on placebo, the placebo trial will have a target of 8 weeks. To provide an opportunity for placebo non-responders to receive active drug and to aid in recruitment, we will provide 8-12 weeks of SSRI treatment to placebo non-responders. This treatment option is something offered to participants outside the clinical trial, and therefore was not treated as part of the main study.
Study NCT04952051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril Folic Acid Tablets Combined With amlodipine
Description: Enalapril Folic Acid Tablets 10.8mg Combined With amlodipine 5 or 10mg
Study NCT04952051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril Folic Acid Tablets Combined With hydrochlorothiazide
Description: Enalapril Folic Acid Tablets 10.8mg Combined With hydrochlorothiazide 12.5 or 25mg
Study NCT01583985 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Opioid-intensive prescribing strategy
Description: The opioid-intensive arm emphasizes early use of strong opioid analgesics. Medications will be individually adjusted according to patient preferences and responses.
Study NCT01583985 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Opioid-avoidant prescribing strategy
Description: The opioid-avoidant prescribing strategy emphasizes non-opioid medications from several drug classes. Medications will be individually adjusted according to patient preferences and responses.
Study NCT03182842 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FreeStyle Libre FGM
Description: Insulin dosing based on FreeStyle Libre FGM system that is indicated for measuring interstitial fluid glucose levels in people (age 4 and older) with diabetes mellitus.
Study NCT03182842 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SMBG - Blinded Sensor
Description: Insulin dosing based on SMBG
Study NCT02905916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Study NCT04378257 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapist Guided E-Therapy
Description: The participants in this group will be allocated weekly sessions with a trained aboard certified clinical psychologist via a web-based e-therapy platform.The link will direct the participant directly to a screen where they will be able to see and interact with the psychologist once a week. The sessions will be conducted in the Arabic or English languages.Following sessions would focus on psychological first aid based on the following interventional tools:~Cognitive Behavior Therapy (CBT)~* Acknowledging emotions and normalizing current stress~* Differentiate dysfunction versus distress (identify any debilitating thoughts/emotions if applicable)~* Behavioral Activation Acceptance and Commitment Therapy (ACT)~* Grounding, Breathing, Acceptance of emotions, and de-fusion
Study NCT04378257 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Help Therapy
Description: The participants in the control group will be supplied with an automatic weekly newsletter through E-mail containing self-help information and tips to cope with distress associated with COVID-19 in Oman. The information will mainly comprise of behavioral tips from principles of CBT and ACT focusing on positive cognitive reinforcement, strengthening relationships and mindfulness practice. The participants will be requested to use this information to manage any distress that they might experience. On the sixth week, the participants in the control group will be assessed on their mood and anxiety symptoms. Participants will also be requested to provide information on other self-help remedies that participants used to improve or manage their functionality (example, access to other websites, communication with close friends or family etc.)
Study NCT02504177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: novel oral anticoagulant for 30 days
Description: novel oral anticoagulant includes 'dabigatran,Pradaxa®', 'rivaroxaban,Xarelto®', and 'apixaban, Eliquis®'.
Study NCT02504177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: novel oral anticoagulant for 24 hour
Description: novel oral anticoagulant includes 'dabigatran,Pradaxa®', 'rivaroxaban,Xarelto®', and 'apixaban, Eliquis®'.
Study NCT02097485 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abametapir Lotion 0.74% w/w
Description: 200mL abametapir lotion topically administered to the scalp and hair and once fully saturated left for 10 minutes and then washed out thoroughly with warm water.
Study NCT02097485 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Lotion
Description: control to abametapir: 200mL Vehicle Lotion topically administered to the scalp and hair and once fully saturated left for 10 minutes and then washed out thoroughly with warm water.
Study NCT02472015 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: telemedicine
Description: psycho-behavioural care by telemedicine
Study NCT03836352 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DPX-Survivac
Description: SubQ injection (q9w)
Study NCT03836352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: PO (BID)
Study NCT03836352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV Infusion (q3w)
Study NCT01938001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375mg/m\^2 IV every week in Cycle 1 (Days 1, 8, 15 and 22) on Day 1 of every 28 day cycle from Cycles 2 to 5
Study NCT03417193 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: opioid free Anesthesia vs Opioid based Anesthesia
Description: Compare the opioid based anesthesia with Fentanyl and Remifentanyl to opioid free anesthesia with dexmedetomidine and lidocaine and their effect on postoperative pain.
Study NCT01993134 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cefazolin
Description: Cefazolin, 2g/IV, prior to surgery, and after surgery recieved 4 aditional doses 1g/IV of Cefazolin.
Study NCT01993134 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin Single Dose
Description: Patients received 2g of Cefazolin (Cefazolin Sodium - Ampoule- 1g - Genéricos Brasil), administered intravenously but none was administered in the post-operative period
Study NCT00115193 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegfilgrastim
Description: pegfilgrastim 6 mg on day 1 of each cycle (within 4 hours of chemotherapy completion)
Study NCT00115193 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegfilgrastim
Description: pegfilgrastim 6 mg on day 2 of each cycle (at least 24 hours after chemotherapy completion)
Study NCT00860626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: interferon α plus nucleoside analogue
Description: Standard dose of interferon is used for 12 weeks. On 12th week of treatment, HBV DNA is still detectable (>1000 copies/ml), or HBeAg is still positive. And lamivudine is added for 3 months. After nucleoside analogue is added for 3 months, HBV DNA is tested again. If negative, stop nucleoside analogue and use interferon alone for another 6 months or longer. If HBV DNA is still positive, change to another nucleoside analogue or add another nucleoside analogue.
Study NCT00860626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: interferon α
Description: Standard dose of interferon is used for 12 weeks.On 12th week of treatment, HBV DNA is still detectable (>1000 copies/ml), or HBeAg is still positive. But no nucleoside analogue is added.
Study NCT00860626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: interferon α
Description: Standard dose of interferon is used for 12 weeks.On 12th week of treatment, HBV DNA is undetectable, or HBeAg is negative. And interferon is continued alone for another 9 months.
Study NCT00006695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Description: 300 mg/m2 IV on Day -6
Study NCT00006695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: 100 mg/m2 BID on Days -5 through -2
Study NCT01938001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab 375mg/m\^2 IV every week in Cycle 1 (Days 1, 8, 15 and 22) on Day 1 of every 28 day cycle from Cycles 2 to 5
Study NCT01938001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 20mg by mouth (PO) daily on Days 1 to 21 every 28 days up to 12 cycles
Study NCT01938001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo (identical matched capsule) PO daily on Days 1 to 21 every 28 days
Study NCT00990249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Test Dose 32 mg/m\^2 by vein over 45 minutes on Day -8; following doses on Days -6 to -3 derived from pharmacokinetic (PK) testing done up to 11 times over 11 hours after test dose.
Study NCT00990249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: 40 mg/m\^2 by vein over 1 hour daily Day -6 through Day -3
Study NCT00990249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: 0.5 mg/kg on Day -3, 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1; only patients with HLA nonidentical or unrelated donors
Study NCT00990249 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: Stem cell infusion on Day 0.
Study NCT01213498 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Zarator, 80 mg pr. day for 5 days
Study NCT01213498 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Unikalk
Description: 1 tablet Unikalk pr day for 5. days
Study NCT01078519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined epidural and spinal anesthesia
Description: Obstetrics patients will relieve spinal anesthesia with local anesthesics and opioids associated with epidural anesthesia with local anesthetics in low concentrations with opioids
Study NCT00751179 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rocuronium
Description: A single bolus intubation dose of 0.6 mg/kg rocuronium will be administered following induction of anesthesia and if required, single bolus dose(s) of 0.15 mg/kg rocuronium will be administered to maintain the neuromuscular block.
Study NCT00751179 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sugammadex
Description: At the end of the surgical procedure at a target depth of neuromuscular blockade of at least 1-2 Post-Tetanic Count (PTC), 4.0 mg/kg of sugammadex will be administered.
Study NCT00751179 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: succinylcholine
Description: A single bolus intubation dose of 1.0 mg/kg succinylcholine will be administered following induction of anesthesia and the subject is allowed to recover spontaneously from the neuromuscular blockade.
Study NCT03104036 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Faecal bacterial transplantation
Description: Enema prepared from 50 g of stool of examined donor dissolved in 150 ml of normal saline
Study NCT03104036 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalazine 4G Enema
Description: Standard mesalazine enema
Study NCT00313248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sagopilone (ZK 219477)
Description: All patients will receive ZK-Epo at a dose of 16mg/m2 as an intravenous infusion. Chemotherapy for recurrent breast cancer.
Study NCT00313248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sagopilone (ZK 219477)
Description: Patients will receive 22mg/m2 as intravenous infusion.